2022 Refresher - Lymphomas
This presentation will help inform listeners about the multidisciplinary care of patients with lymphoma, the use of contemporary treatment fields (e.g. INRT, ISRT), appropriate use of technology (i.e. IMRT, VMAT, deep inspiration breath hold, proton beam therapy), new targeted therapies, immunotherapy, and treatment guidelines. The goal is to provide participants with updates on current clinical and translational initiatives in hematologic malignancies that are relevant to daily clinical practice. Additionally, attendees will be updated on the appropriate integration of these advancements in their daily practice, including indication, patient selection, and combinations of different therapeutic modalities, and management of common toxicities.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents.
Upon completion of this live activity, attendees should be able to do the following:
- Discuss the current guideline-based clinical practice in hematologic malignancies.
- Discuss PET/CT response adaptive radiotherapy protocols for Hodgkin lymphoma and non-Hodgkin lymphoma.
- Explain the application of involved-site radiotherapy (ISRT) for all disease sites – including Hodgkin lymphoma, and non-Hodgkin lymphoma.
- Discuss the importance of multidisciplinary care in hematologic malignancies and how to best apply it for optimal outcomes.
- Describe key advances in immunotherapy and targeted therapy in hematologic malignancies.
- Discuss recent advances in new technology integration (i.e. IMRT, VMAT, deep inspiration breath hold, proton therapy) and how and when to integrate them.
- Discuss late effect of radiotherapy and how to best utilize current knowledge for decision-making.
Bradford Hoppe, MD, MPH is employed by Mayo Clinic and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.